Key facts
- Argonaute RNA’s last known valuation is $11.6M.
- It has raised $5.5M; the latest was Later Stage VC ($2.2M) in Jul 2024.
- Notable investors include Tiny Supercomputer Investment Company, Development Bank of Wales, Empirical Ventures, Bristol Private Equity Club, CatSci — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Argonaute RNA
- ·The full record, as it builds
Funding rounds
No funding rounds for Argonaute RNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Argonaute RNA
Developer of therapeutic medicines designed to harness the body's natural cell mechanisms to combat illness. The company's platform uses a novel method of stabilizing the small interfering ribonucleic acid, thereby avoiding a range of issues that create obstacles, enabling medical practitioners to get effective therapeutics to inhibit the production of specific proteins and treat life-threatening diseases.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2015
- Employees
- 6
- Website
- argonauterna.com/
- Ownership
- Privately Held (backing)
Argonaute RNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Argonaute RNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Argonaute RNA in its N-PORT filings yet. We sweep new filings monthly.